Standout Papers

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial c... 2010 2026 2015 2020 394
  1. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial (2010)
    M. M. Heiss, P. Murawa et al. International Journal of Cancer

Citation Impact

1 by Nobel laureates 2 from Science/Nature 72 standout
Sub-graph 1 of 23

Citing Papers

Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy
2024 Standout
Tumor‐Tailored Ionizable Lipid Nanoparticles Facilitate IL‐12 Circular RNA Delivery for Enhanced Lung Cancer Immunotherapy
2024 Standout
2 intermediate papers

Works of В. В. Іванченко being referenced

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
2010 Standout

Author Peers

Author Mechanical Engineering Surgery PSIR Oncology RNMI Last Decade Papers Cites
В. В. Іванченко 2 110 205 147 7 396
Jessica L. Staib 2 9 5 11 8 599
C. Marino 20 5 179 26 279
W.R. Adano 22 7 274
James A. Johnson 2 17 135 1 17 767
M. J. Holden 7 21 746

All Works

Loading papers...

Rankless by CCL
2026